What is the sentiment of this news? Please choose an answer from {strong negative/moderately negative/mildly negative/neutral/mildly positive/moderately positive/strong positive}.

Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.
mildly negative